Draft guidance from UK's NICE rejects Bristol-Myers Orencia

31 March 2011

US drug major Bristol-Myers Squibb (NYSE: BMY) says that the UK’s drug watchdog the National Institute for Health and Clinical Excellence (NICE ) did not recommend Orencia (abatacept) as a second-line treatment for moderate to severe rheumatoid arthritis in patients who have inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDS).

Currently, the NICE recommends four drugs for second-line use in rheumatoid arthritis including Abbott’s Humira (adalimumab), Pfizer’s Enbrel (etancercept), Merck & Co’s Remicade (infliximab) and UCB’s Cimzia (certolizumab). Analysts at Credit Suisse have a net present value for Orencia of $3.26/share or 9.4% of total NPV for B-MS.

Abatacept is not cost-effective, says agency

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical